IP Library Assignment 069806/0458
Patent Assignment
Reel/Frame 069806/0458

Assignment of Assignor's Interest

Recorded: 2025-01-09 Pages: 20
Assignor
NABRIVA THERAPEUTICS GMBH
Executed: 2024-12-06
Assignee
HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD.
16 XUEFU ROAD, HIGH & NEW TECH DEVELOPMENT ZONE, NANJING, 210061, CHINA
Covered Properties (22)
Organic Compounds
Application: 11/828,224 →
Publication: US 2009/0118366
Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes
Patent: 8,071,643 →
Application: 12/531,839 →
Publication: US 2010/0035987
Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes
Patent: 8,153,689 →
Application: 13/252,732 →
Publication: US 2012/0029072
Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes
Application: 13/438,160 →
Publication: US 2013/0040954
Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes
Application: 14/283,734 →
Publication: US 2014/0256731
Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes
Application: 15/480,756 →
Publication: US 2017/0266194
Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes
Application: 16/023,880 →
Publication: US 2018/0303842
Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes
Application: 16/277,143 →
Publication: US 2019/0175603
Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes
Application: 16/593,449 →
Publication: US 2020/0030335
Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes
Application: 16/881,117 →
Publication: US 2020/0281933
Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes
Application: 17/138,097 →
Publication: US 2021/0113571
Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes
Application: 17/401,418 →
Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes
Application: 17/702,304 →
Publication: US 2022/0218713
Enantiomerically Pure Amines
Patent: 8,987,498 →
Application: 13/699,585 →
Publication: US 2013/0072711
Process for the Preparation of Pleuromutilins
Patent: 9,120,727 →
Application: 13/699,589 →
Publication: US 2013/0079400
Injectable Pharmaceutical Formulations of Lefamulin
Application: 15/736,865 →
Publication: US 2018/0360966
Injectable Pharmaceutical Formulations of Lefamulin
Application: 18/891,571 →
Publication: US 2025/0009885
Purification of Pleuromutilin
Application: 16/482,809 →
Publication: US 2020/0231529
Novel Therapeutic Use of Pleuromutilins
Application: 17/919,202 →
Publication: US 2023/0218558
Therapeutic Use of Pleuromutilins
Application: 17/919,200 →
Publication: US 2023/0174472
Therapeutic Use of Pleuromutilins
Application: 18/837,088 →
Publication: US 2025/0134844
Pleuromutilin Derivatives for the Treatment of Diseases Mediated by Microbes
Patent: 8,071,643 →
Application: 12/531,839 →
Publication: US 2010/0035987
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Dec 18, 2007
From: MANG, ROSEMARIE; HEILMAYER, WERNER; BADEGRUBER, RUDOLF; STRICKMANN, DIRK
To: NABRIVA THERAPEUTICS FORSCHUNGS GMBH
Reel/Frame 020268/0923 →
Assignment of Assignor's Interest Sep 17, 2009
From: MANG, ROSEMARIE; HEILMAYER, WERNER; BADEGRUBER, RUDOLF; STRICKMANN, DIRK B.
To: NABRIVA THERAPEUTICS AG
Reel/Frame 023249/0229 →
Assignment of Assignor's Interest Feb 22, 2012
From: MANG, ROSEMARIE; HEILMAYER, WERNER; BADEGRUBER, RUDOLF; STRICKMANN, DIRK B.
To: NABRIVA THERAPEUTICS AG
Reel/Frame 027745/0615 →
Assignment of Assignor's Interest Nov 27, 2012
From: RIEDL, ROSEMARIE; HEILMAYER, WERNER; SPENCE, LEE; BULUSU, ATCHYUTA RAMA CHANDRA MURTY
To: NABRIVA THERAPEUTICS AG
Reel/Frame 029355/0554 →
Assignment of Assignor's Interest Dec 10, 2012
From: RIEDL, ROSEMARIE; HEILMAYER, WERNER; SPENCE, LEE
To: NABRIVA THERAPEUTICS AG
Reel/Frame 029439/0875 →
Assignment of Assignor's Interest Apr 9, 2013
From: MANG, ROSEMARIE; HEILMAYER, WERNER; BADEGRUBER, RUDOLF; STRICKMANN, DIRK B.
To: NABRIVA THERAPEUTICS AG
Reel/Frame 030177/0294 →
Lien Sep 3, 2014
From: NABRIVA THERAPEUTICS AG
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 033659/0216 →
Assignment of Assignor's Interest Oct 13, 2014
From: NABRIVA THERAPEUTICS AG
To: KREOS CAPITAL IV (UK) LIMITED
Reel/Frame 033935/0048 →
Assignment of Assignor's Interest Oct 13, 2014
From: MANG, ROSEMARIE; HEILMAYER, WERNER; BADEGRUBER, RUDOLF; STRICKMANN, DIRK B.
To: NABRIVA THERAPEUTICS AG
Reel/Frame 033934/0969 →
Release of Security Interest Nov 19, 2015
From: KREOS CAPITAL IV (UK) LIMITED
To: NABRIVA THERAPEUTICS AG
Reel/Frame 037093/0308 →
Corrective Assignment to Correct the Application No. in the Release by Secured Party from 12/699585 to 13/699585 Previously Recorded on Reel 037093 Frame 0308. Assignor(S) Hereby Confirms the Release Agreement. Dec 2, 2015
From: KREOS CAPITAL IV (UK) LIMITED
To: NABRIVA THERAPEUTICS AG
Reel/Frame 037190/0424 →
Release of Security Interest Sep 29, 2016
From: KREOS CAPITAL IV (UK) LIMITED
To: NABRIVA THERAPEUTICS AG
Reel/Frame 039894/0473 →
Assignment of Assignor's Interest Apr 24, 2017
From: MANG, ROSEMARIE; HEILMAYER, WERNER; BADEGRUBER, RUDOLF; STRICKMANN, DIRK B.
To: NABRIVA THERAPEUTICS AG
Reel/Frame 042126/0873 →
Assignment of Assignor's Interest Mar 7, 2018
From: FERENCIC, MATHIAS; HEILMAYER, WERNER; HINSMANN, PETER; WICHA, WOLFGANG
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 045131/0353 →
Change of Name May 17, 2018
From: NABRIVA THERAPEUTICS AG
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 047658/0862 →
Change of Name Jul 18, 2018
From: NABRIVA THERAPEUTICS AG
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 047958/0106 →
Intellectual Property Security Agreement Dec 20, 2018
From: NABRIVA THERAPEUTICS GMBH
To: HERCULES CAPITAL, INC.
Reel/Frame 047973/0110 →
Security Interest Jan 18, 2019
From: NABRIVA THERAPEUTICS GMBH
To: HERCULES CAPITAL, INC.
Reel/Frame 048062/0807 →
Assignment of Assignor's Interest Aug 1, 2019
From: HEILMAYER, WERNER; SPENCE, LEE; HINSMANN, PETER
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 049930/0721 →
First Supplement to Intellectual Property Security Agreement Mar 20, 2020
From: NABRIVA THERAPEUTICS GMBH
To: HERCULES CAPITAL, INC.
Reel/Frame 052201/0503 →
Release of Security Interest Mar 3, 2023
From: HERCULES CAPITAL, INC.
To: NABRIVA THERAPEUTICS GMBH; ZAVANTE THERAPEUTICS, INC.
Reel/Frame 062881/0090 →
Assignment of Assignor's Interest Apr 28, 2023
From: HAFNER, MICHAEL; PAUKNER, SUSANNE; WICHA, WOLFGANG; RIEDL, ROSEMARIE
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 063480/0198 →
Assignment of Assignor's Interest Jun 5, 2023
From: PAUKNER, SUSANNE; WICHA, WOLFGANG; GELONE, STEVEN PETER; ASCHER, GERD
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 063854/0225 →
Corrective Assignment to Correct the Receiving Party Data and the Assignment Document Previously Recorded at Reel: 062881 Frame: 0090. Assignor(S) Hereby Confirms the Release of Security Interest. Jun 20, 2023
From: HERCULES CAPITAL, INC.
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 064312/0350 →
Release of Security Interest Jul 20, 2023
From: HERCULES CAPITAL, INC.
To: NABRIVA THERAPEUTICS GMBH
Reel/Frame 064326/0977 →